RNA Targeting Small Molecule Drug Discovery Market Report 2026

RNA Targeting Small Molecule Drug Discovery Market Overview

• RNA Targeting Small Molecule Drug Discovery market size has reached to $2.13 billion in 2025 • Expected to grow to $6.04 billion in 2030 at a compound annual growth rate (CAGR) of 23.5% • Growth Driver: Rising Disease Burden Is A Catalyst For Growth In RNA-Targeted Small-Molecule Drug Discovery Market • Market Trend: Innovative Solutions In RNA-Targeting Small-Molecule Drug Discovery • North America was the largest region in 2025.

What Is Covered Under RNA Targeting Small Molecule Drug Discovery Market?

RNA targeting small-molecule drug discovery refers to identifying and developing small-molecule drugs that interact with RNA molecules to modulate their function or activity. This process is used for discovering innovative medicines that would be used for treating various diseases, including genetic disorders, viral infections, neurodegenerative diseases, and cancer. The main target RNA types included in RNA targeting small molecule drug discovery are messenger RNA (mRNA), non-coding RNA (ncRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). Messenger RNA (mRNA) is an RNA molecule that carries genetic information from the DNA in the cell's nucleus to the ribosomes, where protein synthesis occurs. The various technologies are CRISPR-cas9, RNA aptamers, small interfering RNA (siRNA), ribozymes, and others used in multiple therapeutic areas such as oncology, neurology, infectious disease, metabolic diseases, genetic disorders, and others. The various delivery methods are intravenous (IV), oral, topical, and others applied in research use, therapeutic use, diagnostic use, and others.

What Is The RNA Targeting Small Molecule Drug Discovery Market Growth Forecast?

The rna targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $6.04 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to ai-enabled rna target identification, increasing investment in precision medicine, expansion of rna therapeutics pipelines, improved rna delivery technologies, regulatory support for novel modalities. Major trends in the forecast period include ai-driven rna structure prediction, expansion of rna-targeted oncology pipelines, advances in rna-specific small molecule libraries, improved rna binding selectivity and specificity, integration of multi-omics in rna drug discovery.

Global RNA Targeting Small Molecule Drug Discovery Market Segmentation

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA) 2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas 3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods 4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications Subsegments: 1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition 2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA 3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways 4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

What Is The Driver Of The RNA Targeting Small Molecule Drug Discovery Market?

The increasing prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market going forward. Cancer is a group of diseases characterized by the uncontrollable growth of cells in the body. Viral infections refer to infections caused by viruses, tiny infectious agents that can only replicate inside the cells of living organisms. RNA targeting-based drug discovery is used to treat cancer, genetic disorders, and viral infections, as these diseases are linked with genes and malfunctioning genetic material, which can be treated using drugs developed using RNA targeting-based methods. For instance, in February 2024, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there were an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most common, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are expected to rise by 77%, reaching over 35 million annually. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections drives the growth of the RNA-targeted small-molecule drug discovery market.

Key Players In The Global RNA Targeting Small Molecule Drug Discovery Market

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Global RNA Targeting Small Molecule Drug Discovery Market Trends and Insights

Major companies operating in the RNA-targeting small-molecule drug discovery market are developing innovative platforms such as software-as-a-service platforms to gain a competitive edge in the market. Software-as-a-service (SaaS) is a software distribution model where applications are hosted by a third-party provider and made available to customers over the Internet. For instance, in December 2023, Merck & Co. Inc. a US-based science and technology company launched AIDDISON. The platform suggests the best ways to synthesize these selected medications. This innovative approach could result in huge cost savings for the drug discovery process and greatly increase the success rate of introducing novel medicines to patients. By bridging the gap between virtual molecular design and real-world manufacturability, the platform increases the success rate of delivering innovative treatments to patients by extracting hidden insights from large datasets. To accelerate the medication development process, this novel AI system integrates computer-aided drug design, machine learning, and generative AI.

What Are Latest Mergers And Acquisitions In The RNA Targeting Small Molecule Drug Discovery Market?

In June 2025, Novartis AG, a Switzerland-based provider of pharmaceuticals, gene therapies, and innovative medicines, acquired Regulus Therapeutics Inc. for up to $ 1.7 billion. Through this acquisition, Novartis aims to strengthen its renal-disease pipeline by accessing Regulus’s lead microRNA inhibitor for autosomal dominant polycystic kidney disease (ADPKD) and advancing RNA-targeted drug discovery. Regulus Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs.

Regional Insights

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the RNA Targeting Small Molecule Drug Discovery Market?

The RNA targeting small molecule drug discovery market consists of revenues earned by entities by providing hit identification, hit validation, and hit characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA-targeting small molecule drug discovery market also includes sales of asRNAs and siRNAs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the RNA Targeting Small Molecule Drug Discovery Market Report 2026?

The rna targeting small molecule drug discovery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rna targeting small molecule drug discovery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.